This HTML5 document contains 79 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n8http://linked.opendata.cz/resource/drugbank/drug/DB06771/identifier/national-drug-code-directory/
n18http://linked.opendata.cz/resource/AHFS/
foafhttp://xmlns.com/foaf/0.1/
n12http://linked.opendata.cz/resource/drugbank/dosage/
n14http://www.drugs.com/
n11http://www.rxlist.com/
n16http://bio2rdf.org/drugbank:
n6http://linked.opendata.cz/resource/drugbank/drug/DB06771/identifier/wikipedia/
admshttp://www.w3.org/ns/adms#
n13http://linked.opendata.cz/resource/drugbank/patent/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n5http://linked.opendata.cz/ontology/drugbank/
n9http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n7http://linked.opendata.cz/resource/drugbank/drug/DB06771/identifier/kegg-drug/
n4http://linked.opendata.cz/resource/drugbank/drug/DB06771/identifier/drugbank/
n20http://linked.opendata.cz/resource/atc/
n17http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB06771
rdf:type
n5:Drug
n5:description
Besifloxacin is a fourth generation fluoroquinolone-type opthalmic antibiotic for the treatment of bacterial conjunctivitis. FDA approved on May 28, 2009.
n5:dosage
n12:271B53C2-363D-11E5-9242-09173F13E4C5 n12:271B53C1-363D-11E5-9242-09173F13E4C5
n5:generalReferences
# O'Brien TP: Besifloxacin ophthalmic suspension, 0.6%: a novel topical fluoroquinolone for bacterial conjunctivitis. Adv Ther. 2012 Jun;29(6):473-90. doi: 10.1007/s12325-012-0027-7. Epub 2012 Jun 20. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/22729919 # Proksch JW, Granvil CP, Siou-Mermet R, Comstock TL, Paterno MR, Ward KW: Ocular pharmacokinetics of besifloxacin following topical administration to rabbits, monkeys, and humans. J Ocul Pharmacol Ther. 2009 Aug;25(4):335-44. doi: 10.1089/jop.2008.0116. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/19492955
n5:group
approved
n5:halfLife
The average elimination half-life of besifloxacin in plasma following multiple dosing was estimated to be 7 hours.
n5:indication
Treatment of bacterial conjunctivitis. Bacterial isolates that are susceptible to besifloxacin include: CDC coryneform group G; Corynebacterium pseudodiphtheriticum; Corynebacterium striatum; Haemophilus influenzae; Moraxella lacunata; Staphylococcus aureus; Staphylococcus epidermidis; Staphylococcus hominis; Staphylococcus lugdunensis; Streptococcus mitis group; Streptococcus oralis; Streptococcus pneumoniae; Streptococcus salivarius*
owl:sameAs
n16:DB06771
dcterms:title
Besifloxacin
adms:identifier
n4:DB06771 n6:Besifloxacin n7:D08872 n8:54868-6282-0
n5:mechanismOfAction
Besifloxacin is a bactericidal fluroquinolone-type antibiotic that inhibits bacterial enzymes, DNA gyrase and topoisomerase IV. By inhibiting DNA gyrase, DNA replication, transcription, and repair is impaired. By inhibiting topoisomerase IV, decatenation during cell devision is impaired. Inhibiting these two targets also slows down development of resistance.
n5:patent
n13:5%2C447%2C926 n13:6%2C685%2C958 n13:6%2C699%2C492
n5:routeOfElimination
N/A
n5:synonym
SS734 Besifloxacin
n5:toxicity
LD50, rat: >2000 mg/kg. The most common adverse reaction reported in 2% of patients treated with besifloxacin was conjunctival redness.
n5:volumeOfDistribution
Not absorbed into the systemic
n17:hasAHFSCode
n18:52-04-04
n5:proteinBinding
None
n5:salt
foaf:page
n11:besivance-drug.htm n14:besivance.html
n5:IUPAC-Name
n9:271B53C7-363D-11E5-9242-09173F13E4C5
n5:InChI
n9:271B53CD-363D-11E5-9242-09173F13E4C5
n5:Molecular-Formula
n9:271B53CC-363D-11E5-9242-09173F13E4C5
n5:Molecular-Weight
n9:271B53C9-363D-11E5-9242-09173F13E4C5
n5:Monoisotopic-Weight
n9:271B53CA-363D-11E5-9242-09173F13E4C5
n5:SMILES
n9:271B53CB-363D-11E5-9242-09173F13E4C5
n5:Water-Solubility
n9:271B53C5-363D-11E5-9242-09173F13E4C5 n9:271B53DD-363D-11E5-9242-09173F13E4C5
n5:logP
n9:271B53C6-363D-11E5-9242-09173F13E4C5 n9:271B53C3-363D-11E5-9242-09173F13E4C5
n5:logS
n9:271B53C4-363D-11E5-9242-09173F13E4C5
n5:pKa
n9:271B53DE-363D-11E5-9242-09173F13E4C5
n17:hasATCCode
n20:S01AE08
n5:H-Bond-Acceptor-Count
n9:271B53D3-363D-11E5-9242-09173F13E4C5
n5:H-Bond-Donor-Count
n9:271B53D4-363D-11E5-9242-09173F13E4C5
n5:InChIKey
n9:271B53CE-363D-11E5-9242-09173F13E4C5
n5:Polar-Surface-Area--PSA-
n9:271B53CF-363D-11E5-9242-09173F13E4C5
n5:Polarizability
n9:271B53D1-363D-11E5-9242-09173F13E4C5
n5:Refractivity
n9:271B53D0-363D-11E5-9242-09173F13E4C5
n5:Rotatable-Bond-Count
n9:271B53D2-363D-11E5-9242-09173F13E4C5
n5:absorption
Although ocular surface concentrations are high, average systemic concentrtions after three-times daily dosing was less than 0.5 ng/mL. This indicates that besifloxacin is not appreciably absorbed into the systemic and has a very low risk of systemic side effects.
n5:affectedOrganism
Staphylococcus hominis Corynebacterium sp. G Haemophilus influenzae Staphylococcus lugdunensis Streptococcus mitis Corynebacterium striatum Streptococcus salivarius Staphylococcus warneri Streptococcus oralis Moraxella catarrhalis Gram negative and gram positive bacteria Staphylococcus aureus Streptococcus pneumoniae Corynebacterium pseudodiphtheriticum Staphylococcus epidermidis Pseudomonas aeruginosa Aerococcus viridans Moraxella lacunata
n5:casRegistryNumber
141388-76-3
n5:category
n5:clearance
N/A
n5:Bioavailability
n9:271B53D9-363D-11E5-9242-09173F13E4C5
n5:Ghose-Filter
n9:271B53DB-363D-11E5-9242-09173F13E4C5
n5:MDDR-Like-Rule
n9:271B53DC-363D-11E5-9242-09173F13E4C5
n5:Number-of-Rings
n9:271B53D8-363D-11E5-9242-09173F13E4C5
n5:Physiological-Charge
n9:271B53D7-363D-11E5-9242-09173F13E4C5
n5:Rule-of-Five
n9:271B53DA-363D-11E5-9242-09173F13E4C5
n5:Traditional-IUPAC-Name
n9:271B53C8-363D-11E5-9242-09173F13E4C5
n5:pKa--strongest-acidic-
n9:271B53D5-363D-11E5-9242-09173F13E4C5
n5:pKa--strongest-basic-
n9:271B53D6-363D-11E5-9242-09173F13E4C5